Pancreatic Cancer Research

ResearcherInsermActive in the last 2 years

Thierry André

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5103-7095; OpenAlex author ID A5079480540. Sources: OpenAlex.

Their work

Papers
20 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
50
Papers, trials and grants by year

2012: 2 papers · 2013: 1 paper · 2014: none · 2015: 5 papers · 2016: 3 papers · 2017: 1 paper · 2018: none · 2019: 2 papers · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 20

  1. Emergency integrative supportive care program for frail patients with advanced pancreatic cancer: A prospective GERCOR ARCAD study Co-author DOI 10.64898/2026.06.18.26355998↗
  2. Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PROD… Co-author DOI 10.1200/jco-24-01378↗
  3. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2022.3829↗
  4. Ovarian metastases of pancreatic adenocarcinoma: clinical presentation, role of surgery, and potential value of the mutational profile for the differential dia… Co-author DOI 10.1177/17588359211053412↗
  5. Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized … Co-author DOI 10.1016/j.ejca.2019.10.020↗
  6. Erratum to 'Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label,… Co-author DOI 10.1016/j.ejca.2020.02.004↗
  7. Pancreatic ductal adenocarcinoma harboring microsatellite instability / DNA mismatch repair deficiency. Towards personalized medicine. Co-author DOI 10.1016/j.suronc.2018.11.019↗
  8. Long-Term Survival in Locally Advanced KRAS Wild-Type Pancreatic Adenocarcinoma. Last author DOI 10.1155/2019/8598635↗
  9. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR)… Co-author DOI 10.1016/s2468-1253(17)30046-8↗
  10. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Wi… Co-author DOI 10.1001/jama.2016.4324↗
  11. [New molecular classification of colorectal cancer, pancreatic cancer and stomach cancer: Towards "à la carte" treatment?]. Last author DOI 10.1016/j.bulcan.2016.05.007↗
  12. Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP). Co-author DOI 10.1038/bjc.2016.212↗
  13. Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retro… Co-author DOI 10.1016/j.clinthera.2015.03.016↗
  14. [Is it necessary to perform a surgery after neo-adjuvant treatment for initially borderline or locally advanced pancreatic adenocarcinoma?]. Co-author DOI 10.1016/s0007-4551(15)31229-7↗
  15. Asparagine Synthetase Expression and Phase I Study With L-Asparaginase Encapsulated in Red Blood Cells in Patients With Pancreatic Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000000394↗
  16. Sonic hedgehog and Gli1 expression predict outcome in resected pancreatic adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-14-0667↗
  17. A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer:… Co-author DOI 10.1186/s12885-015-1656-4↗
  18. S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ejca.2013.04.017↗
  19. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Co-author DOI 10.1053/j.gastro.2012.06.006↗
  20. Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. Co-author DOI 10.1093/annonc/mdr617↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Pascal R. Hammel · 13 shared papers, 2012–2026 · strength 0.88
  2. Jean‐Baptiste Bachet · 11 shared papers, 2012–2026 · strength 0.78
  3. Christophe Louvet · 11 shared papers, 2012–2026 · strength 0.71
  4. Jerome F. Cros · 7 shared papers, 2013–2026 · strength 0.62
  5. Christophe Tournigand · 4 shared papers, 2017–2026 · strength 0.44
  6. Magali Svrcek · 7 shared papers, 2012–2021 · strength 0.40
  7. Christelle de la Fouchardière · 3 shared papers, 2020–2026 · strength 0.39
  8. François Paye · 6 shared papers, 2012–2021 · strength 0.34
  9. Isabelle Trouilloud · 2 shared papers, 2016–2026 · strength 0.31
  10. Déwi Vernerey · 2 shared papers, 2016–2026 · strength 0.27
  11. Franck Bonnetain · 6 shared papers, 2012–2017 · strength 0.26
  12. Yves Rinaldi · 1 shared paper, 2026 · strength 0.22
  13. Cindy Neuzillet · 1 shared paper, 2026 · strength 0.22
  14. Benoı̂t Rousseau · 1 shared paper, 2026 · strength 0.22
  15. Marc Hilmi · 1 shared paper, 2026 · strength 0.22
  16. Aurélien Lambert · 1 shared paper, 2026 · strength 0.22
  17. Romain Coriat · 1 shared paper, 2026 · strength 0.22
  18. Olivier Bouché · 3 shared papers, 2016–2020 · strength 0.22
  19. Jean‐Luc Van Laethem · 6 shared papers, 2012–2016 · strength 0.21
  20. Iman El Hariry · 2 shared papers, 2020 · strength 0.17
  21. Fabienne Portales · 2 shared papers, 2020 · strength 0.17
  22. David Tougeron · 2 shared papers, 2020 · strength 0.17
  23. Raphaël Maréchal · 5 shared papers, 2012–2015 · strength 0.15
  24. Pieter Demetter · 5 shared papers, 2012–2015 · strength 0.15
  25. Romain Cohen · 1 shared paper, 2019 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.